Edwards Lifesciences Corporation (EW)
USD 70.74
(2.23%)
USD 70.74
(2.23%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.64 Billion USD | 6.36% |
| 2022 | 2.48 Billion USD | -6.78% |
| 2021 | 2.66 Billion USD | 0.15% |
| 2020 | 2.66 Billion USD | 13.8% |
| 2019 | 2.33 Billion USD | 7.17% |
| 2018 | 2.18 Billion USD | -19.19% |
| 2017 | 2.7 Billion USD | 42.88% |
| 2016 | 1.89 Billion USD | 21.51% |
| 2015 | 1.55 Billion USD | 16.75% |
| 2014 | 1.33 Billion USD | 14.36% |
| 2013 | 1.16 Billion USD | 57.03% |
| 2012 | 742.2 Million USD | 15.5% |
| 2011 | 642.6 Million USD | 40.0% |
| 2010 | 459 Million USD | 0.31% |
| 2009 | 457.6 Million USD | -12.24% |
| 2008 | 521.4 Million USD | 2.22% |
| 2007 | 510.1 Million USD | 2.55% |
| 2006 | 497.4 Million USD | -7.74% |
| 2005 | 539.1 Million USD | 11.25% |
| 2004 | 484.6 Million USD | 3.92% |
| 2003 | 466.3 Million USD | -0.53% |
| 2002 | 468.8 Million USD | -8.79% |
| 2001 | 514 Million USD | -20.68% |
| 2000 | 648 Million USD | 204.23% |
| 1999 | 213 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 2.59 Billion USD | 1.76% |
| 2024 Q1 | 2.54 Billion USD | -3.55% |
| 2023 Q4 | 2.64 Billion USD | 0.0% |
| 2023 Q1 | 2.58 Billion USD | 4.16% |
| 2023 Q2 | 2.55 Billion USD | -1.22% |
| 2023 Q3 | 2.64 Billion USD | 3.37% |
| 2023 FY | 2.64 Billion USD | 6.36% |
| 2022 Q4 | 2.48 Billion USD | 2.7% |
| 2022 Q3 | 2.42 Billion USD | -2.46% |
| 2022 Q1 | 2.57 Billion USD | -3.44% |
| 2022 Q2 | 2.48 Billion USD | -3.63% |
| 2022 FY | 2.48 Billion USD | -6.78% |
| 2021 Q2 | 2.52 Billion USD | -1.04% |
| 2021 Q4 | 2.66 Billion USD | 1.82% |
| 2021 FY | 2.66 Billion USD | 0.15% |
| 2021 Q1 | 2.55 Billion USD | -4.04% |
| 2021 Q3 | 2.61 Billion USD | 3.57% |
| 2020 Q1 | 2.17 Billion USD | -7.04% |
| 2020 Q2 | 2.58 Billion USD | 18.85% |
| 2020 FY | 2.66 Billion USD | 13.8% |
| 2020 Q4 | 2.66 Billion USD | 2.79% |
| 2020 Q3 | 2.59 Billion USD | 0.21% |
| 2019 Q1 | 2.02 Billion USD | -7.4% |
| 2019 Q3 | 2.15 Billion USD | 3.78% |
| 2019 FY | 2.33 Billion USD | 7.17% |
| 2019 Q4 | 2.33 Billion USD | 8.75% |
| 2019 Q2 | 2.07 Billion USD | 2.54% |
| 2018 Q1 | 2.57 Billion USD | -4.53% |
| 2018 FY | 2.18 Billion USD | -19.19% |
| 2018 Q4 | 2.18 Billion USD | -15.93% |
| 2018 Q2 | 2.52 Billion USD | -2.23% |
| 2018 Q3 | 2.59 Billion USD | 2.97% |
| 2017 Q2 | 2.19 Billion USD | 7.91% |
| 2017 FY | 2.7 Billion USD | 42.88% |
| 2017 Q4 | 2.7 Billion USD | 16.16% |
| 2017 Q3 | 2.32 Billion USD | 5.78% |
| 2017 Q1 | 2.03 Billion USD | 7.76% |
| 2016 Q3 | 1.64 Billion USD | 4.24% |
| 2016 Q1 | 1.55 Billion USD | -0.11% |
| 2016 Q4 | 1.89 Billion USD | 14.8% |
| 2016 FY | 1.89 Billion USD | 21.51% |
| 2016 Q2 | 1.58 Billion USD | 1.65% |
| 2015 Q3 | 1.45 Billion USD | 10.27% |
| 2015 Q1 | 1.27 Billion USD | -4.38% |
| 2015 FY | 1.55 Billion USD | 16.75% |
| 2015 Q2 | 1.31 Billion USD | 3.55% |
| 2015 Q4 | 1.55 Billion USD | 6.94% |
| 2014 Q3 | 1.3 Billion USD | -7.44% |
| 2014 Q1 | 1.31 Billion USD | 12.48% |
| 2014 Q2 | 1.41 Billion USD | 7.69% |
| 2014 FY | 1.33 Billion USD | 14.36% |
| 2014 Q4 | 1.33 Billion USD | 2.01% |
| 2013 Q2 | 759.9 Million USD | 7.85% |
| 2013 Q3 | 1.09 Billion USD | 43.86% |
| 2013 Q4 | 1.16 Billion USD | 6.61% |
| 2013 FY | 1.16 Billion USD | 57.03% |
| 2013 Q1 | 704.6 Million USD | -5.07% |
| 2012 Q4 | 742.2 Million USD | 12.54% |
| 2012 FY | 742.2 Million USD | 15.5% |
| 2012 Q3 | 659.5 Million USD | 2.97% |
| 2012 Q2 | 640.5 Million USD | 4.33% |
| 2012 Q1 | 613.9 Million USD | -4.47% |
| 2011 FY | 642.6 Million USD | 40.0% |
| 2011 Q4 | 642.6 Million USD | 2.28% |
| 2011 Q3 | 628.3 Million USD | 1.8% |
| 2011 Q2 | 617.2 Million USD | 7.66% |
| 2011 Q1 | 573.3 Million USD | 24.9% |
| 2010 FY | 459 Million USD | 0.31% |
| 2010 Q2 | 524.1 Million USD | 15.72% |
| 2010 Q4 | 459 Million USD | -6.69% |
| 2010 Q3 | 491.9 Million USD | -6.14% |
| 2010 Q1 | 452.9 Million USD | -1.03% |
| 2009 Q4 | 457.6 Million USD | -8.02% |
| 2009 Q3 | 497.5 Million USD | 7.68% |
| 2009 Q1 | 415.6 Million USD | -20.29% |
| 2009 Q2 | 462 Million USD | 11.16% |
| 2009 FY | 457.6 Million USD | -12.24% |
| 2008 FY | 521.4 Million USD | 2.22% |
| 2008 Q1 | 532.7 Million USD | 4.43% |
| 2008 Q2 | 451 Million USD | -15.34% |
| 2008 Q3 | 506.7 Million USD | 12.35% |
| 2008 Q4 | 521.4 Million USD | 2.9% |
| 2007 Q4 | 510.1 Million USD | 7.19% |
| 2007 Q1 | 464.2 Million USD | -6.67% |
| 2007 Q2 | 444.3 Million USD | -4.29% |
| 2007 Q3 | 475.9 Million USD | 7.11% |
| 2007 FY | 510.1 Million USD | 2.55% |
| 2006 Q3 | 512.4 Million USD | -4.55% |
| 2006 FY | 497.4 Million USD | -7.74% |
| 2006 Q4 | 497.4 Million USD | -2.93% |
| 2006 Q2 | 536.8 Million USD | 4.03% |
| 2006 Q1 | 516 Million USD | -4.28% |
| 2005 Q2 | 489.1 Million USD | 2.97% |
| 2005 Q4 | 539.1 Million USD | 10.97% |
| 2005 Q3 | 485.8 Million USD | -0.67% |
| 2005 FY | 539.1 Million USD | 11.25% |
| 2005 Q1 | 475 Million USD | -1.98% |
| 2004 Q1 | 533.6 Million USD | 14.43% |
| 2004 Q2 | 503.4 Million USD | -5.66% |
| 2004 Q3 | 472.6 Million USD | -6.12% |
| 2004 Q4 | 484.6 Million USD | 2.54% |
| 2004 FY | 484.6 Million USD | 3.92% |
| 2003 Q4 | 466.3 Million USD | -5.24% |
| 2003 Q1 | 492.9 Million USD | 5.14% |
| 2003 Q2 | 520.7 Million USD | 5.64% |
| 2003 FY | 466.3 Million USD | -0.53% |
| 2003 Q3 | 492.1 Million USD | -5.49% |
| 2002 Q3 | 459.6 Million USD | -8.76% |
| 2002 Q4 | 468.8 Million USD | 2.0% |
| 2002 Q2 | 503.7 Million USD | 5.13% |
| 2002 Q1 | 479.1 Million USD | -6.79% |
| 2002 FY | 468.8 Million USD | -8.79% |
| 2001 FY | 514 Million USD | -20.68% |
| 2001 Q1 | 638.9 Million USD | -1.4% |
| 2001 Q4 | 514 Million USD | -6.03% |
| 2001 Q3 | 547 Million USD | -7.52% |
| 2001 Q2 | 591.5 Million USD | -7.42% |
| 2000 FY | 648 Million USD | 204.23% |
| 2000 Q4 | 648 Million USD | -4.9% |
| 2000 Q3 | 681.4 Million USD | -4.3% |
| 2000 Q2 | 712 Million USD | 2.01% |
| 2000 Q1 | 698 Million USD | 227.7% |
| 1999 Q4 | 213 Million USD | 0.0% |
| 1999 FY | 213 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Abbott Laboratories | 34.38 Billion USD | 92.312% |
| Allurion Technologies Inc. | 142.19 Million USD | -1759.225% |
| Artivion, Inc. | 510.61 Million USD | -417.766% |
| Avanos Medical, Inc. | 456.1 Million USD | -479.654% |
| Butterfly Network, Inc. | 84.22 Million USD | -3039.122% |
| Butterfly Network, Inc. | 84.22 Million USD | -3039.122% |
| Bio-Rad Laboratories, Inc. | 3.55 Billion USD | 25.693% |
| Boston Scientific Corporation | 15.6 Billion USD | 83.059% |
| CONMED Corporation | 1.46 Billion USD | -80.366% |
| Paragon 28, Inc. | 162.95 Million USD | -1522.381% |
| Glaukos Corporation | 478.64 Million USD | -452.347% |
| Globus Medical, Inc. | 1.08 Billion USD | -142.969% |
| Inspire Medical Systems, Inc. | 104.29 Million USD | -2434.876% |
| Integer Holdings Corporation | 1.41 Billion USD | -87.076% |
| Medtronic plc | 39.56 Billion USD | 93.317% |
| Myomo, Inc. | 5.59 Million USD | -47176.412% |
| Nevro Corp. | 330.31 Million USD | -700.397% |
| Owlet, Inc. | 73.79 Million USD | -3482.433% |
| Penumbra, Inc. | 377.36 Million USD | -600.602% |
| Vicarious Surgical Inc. | 21.89 Million USD | -11974.903% |
| Smith & Nephew plc | 4.77 Billion USD | 44.574% |
| Sonendo, Inc. | 49.74 Million USD | -5215.132% |
| STERIS plc | 4.74 Billion USD | 44.322% |
| Stryker Corporation | 21.31 Billion USD | 87.599% |
| Vapotherm, Inc. | 132.95 Million USD | -1888.552% |
| Zimmer Biomet Holdings, Inc. | 9 Billion USD | 70.653% |